|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Edwards BK, Ward E, Kohler BA, Eheman C,
Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lansdorp-Vogelaar I,
Seeff LC, et al: Annual report to the nation on the status of
cancer, 1975–2006, featuring colorectal cancer trends and impact of
interventions (risk factors, screening, and treatment) to reduce
future rates. Cancer. 116:544–573. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Center MM, Jemal A and Ward E:
International trends in colorectal cancer incidence rates. Cancer
Epidemiol Biomarkers Prev. 18:1688–1694. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Center MM, Jemal A, Smith RA and Ward E:
Worldwide variations in colorectal cancer. CA Cancer J Clin.
59:366–378. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ramasamy TS, Ayob AZ, Myint HHL,
Thiagarajah S and Amini F: Targeting colorectal cancer stem cells
using curcumin and curcumin analogues: Insights into the mechanism
of the therapeutic efficacy. Cancer Cell Int. 15:962015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Donnenberg VS and Donnenberg AD: Multiple
drug resistance in cancer revisited: The cancer stem cell
hypothesis. J Clin Pharmacol. 45:872–877. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dean M: ABC transporters, drug resistance,
and cancer stem cells. J Mammary Gland Biol Neoplasia. 14:3–9.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Clarke MF, Dick JE, Dirks PB, Eaves CJ,
Jamieson CH, Jones DL, Visvader J, Weissman IL and Wahl GM: Cancer
stem cells - perspectives on current status and future directions:
AACR Workshop on cancer stem cells. Cancer Res. 66:9339–9344. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Visvader JE and Lindeman GJ: Cancer stem
cells in solid tumours: Accumulating evidence and unresolved
questions. Nat Rev Cancer. 8:755–768. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dalerba P, Dylla SJ, Park I-K, Liu R, Wang
X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, et al:
Phenotypic characterization of human colorectal cancer stem cells.
Proc Natl Acad Sci USA. 104:10158–10163. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ricci-Vitiani L, Lombardi DG, Pilozzi E,
Biffoni M, Todaro M, Peschle C and De Maria R: Identification and
expansion of human colon-cancer-initiating cells. Nature.
445:111–115. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lugli A, Iezzi G, Hostettler I, Muraro MG,
Mele V, Tornillo L, Carafa V, Spagnoli G, Terracciano L and Zlobec
I: Prognostic impact of the expression of putative cancer stem cell
markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer.
Br J Cancer. 103:382–390. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Meng H-M, Zheng P, Wang X-Y, Liu C, Sui
H-M, Wu S-J, Zhou J, Ding Y-Q and Li J: Over-expression of Nanog
predicts tumor progression and poor prognosis in colorectal cancer.
Cancer Biol Ther. 9:295–302. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Saigusa S, Tanaka K, Toiyama Y, Yokoe T,
Okugawa Y, Ioue Y, Miki C and Kusunoki M: Correlation of CD133,
OCT4, and SOX2 in rectal cancer and their association with distant
recurrence after chemoradiotherapy. Ann Surg Oncol. 16:3488–3498.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jeter CR, Liu B, Liu X, Chen X, Liu C,
Calhoun-Davis T, Repass J, Zaehres H, Shen JJ and Tang DG: NANOG
promotes cancer stem cell characteristics and prostate cancer
resistance to androgen deprivation. Oncogene. 30:3833–3845. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kodach LL, Jacobs RJ, Voorneveld PW,
Wildenberg ME, Verspaget HW, van Wezel T, Morreau H, Hommes DW,
Peppelenbosch MP, van den Brink GR, et al: Statins augment the
chemosensitivity of colorectal cancer cells inducing epigenetic
reprogramming and reducing colorectal cancer cell ‘stemness’ via
the bone morphogenetic protein pathway. Gut. 60:1544–1553. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yin PH, Liu X, Qiu YY, Cai JF, Qin JM, Zhu
HR and Li Q: Anti-tumor activity and apoptosis-regulation
mechanisms of bufalin in various cancers: New hope for cancer
patients. Asian Pac J Cancer Prev. 13:5339–5343. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang J, Chen C, Wang S, Zhang Y, Yin P,
Gao Z, Xu J, Feng D, Zuo Q, Zhao R, et al: Bufalin inhibits HCT116
colon cancer cells and its orthotopic xenograft tumor in mice model
through genes related to apoptotic and PTEN/AKT pathways.
Gastroenterol Res Pract. 2015:4571932015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Qiu YY, Hu Q, Tang QF, Feng W, Hu SJ,
Liang B, Peng W and Yin PH: MicroRNA-497 and bufalin act
synergistically to inhibit colorectal cancer metastasis. Tumour
Biol. 35:2599–2606. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu T, Jia T, Yuan X, Liu C, Sun J, Ni Z,
Xu J, Wang X and Yuan Y: Development of octreotide-conjugated
polymeric prodrug of bufalin for targeted delivery to somatostatin
receptor 2 overexpressing breast cancer in vitro and in vivo. Int J
Nanomed. 11:2235–2250. 2016.
|
|
23
|
Zhao H, Zhao D, Jin H, Li H, Yang X,
Zhuang L and Liu T: Bufalin reverses intrinsic and acquired drug
resistance to cisplatin through the AKT signaling pathway in
gastric cancer cells. Mol Med Rep. 14:1817–1822. 2016.PubMed/NCBI
|
|
24
|
Wu SH, Bau DT, Hsiao YT, Lu KW, Hsia TC,
Lien JC, Ko YC, Hsu WH, Yang ST, Huang YP, et al: Bufalin induces
apoptosis in vitro and has Antitumor activity against human lung
cancer xenografts in vivo. Environ Toxicol. 32:1305–1317. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xie CM, Chan WY, Yu S, Zhao J and Cheng
CH: Bufalin induces autophagy-mediated cell death in human colon
cancer cells through reactive oxygen species generation and JNK
activation. Free Radic Biol Med. 51:1365–1375. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chang Y, Zhao Y, Gu W, Cao Y, Wang S, Pang
J and Shi Y: Bufalin inhibits the differentiation and proliferation
of cancer stem cells derived from primary osteosarcoma cells
through mir-148a. Cell Physiol Biochem. 36:1186–1196. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chang Y, Zhao Y, Zhan H, Wei X, Liu T and
Zheng B: Bufalin inhibits the differentiation and proliferation of
human osteosarcoma cell line hMG63-derived cancer stem cells.
Tumour Biol. 35:1075–1082. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang H, Ning Z, Li Y, Zhu X and Meng Z:
Bufalin suppresses cancer stem-like cells in gemcitabine-resistant
pancreatic cancer cells via Hedgehog signaling. Mol Med Rep.
14:1907–1914. 2016.PubMed/NCBI
|
|
29
|
Gai JQ, Sheng X, Qin JM, Sun K, Zhao W and
Ni L: The effect and mechanism of bufalin on regulating
hepatocellular carcinoma cell invasion and metastasis via
Wnt/β-catenin signaling pathway. Int J Oncol. 48:338–348.
2016.PubMed/NCBI
|
|
30
|
Zhu Z, Sun H, Ma G, Wang Z, Li E and Liu Y
and Liu Y: Bufalin induces lung cancer cell apoptosis via the
inhibition of PI3K/Akt pathway. Int J Mol Sci. 13:2025–2035. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhu Z, Li E, Liu Y, Gao Y, Sun H, Ma G,
Wang Z, Liu X, Wang Q, Qu X, et al: Inhibition of Jak-STAT3 pathway
enhances bufalin-induced apoptosis in colon cancer SW620 cells.
World J Surg Oncol. 10:2282012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bertrand FE, Angus CW, Partis WJ and
Sigounas G: Developmental pathways in colon cancer: Crosstalk
between WNT, BMP, Hedgehog and Notch. Cell Cycle. 11:4344–4351.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cao L, Zhou Y, Zhai B, Liao J, Xu W, Zhang
R, Li J, Zhang Y, Chen L, Qian H, et al: Sphere-forming cell
subpopulations with cancer stem cell properties in human hepatoma
cell lines. BMC Gastroenterol. 11:712011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen S-F, Chang Y-C, Nieh S, Liu C-L, Yang
C-Y and Lin Y-S: Nonadhesive culture system as a model of rapid
sphere formation with cancer stem cell properties. PLoS One.
7:e318642012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jung MJ, Rho JK, Kim YM, Jung JE, Jin YB,
Ko YG, Lee JS, Lee SJ, Lee JC and Park MJ: Upregulation of CXCR4 is
functionally crucial for maintenance of stemness in drug-resistant
non-small cell lung cancer cells. Oncogene. 32:209–221. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Levina V, Marrangoni AM, DeMarco R,
Gorelik E and Lokshin AE: Drug-selected human lung cancer stem
cells: Cytokine network, tumorigenic and metastatic properties.
PLoS One. 3:e30772008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hamilton G and Olszewski U:
Chemotherapy-induced enrichment of cancer stem cells in lung
cancer. J Bioanal Biomed. S9:2013.doi:10.4172/1948-593X.S9-003.
|
|
38
|
Sun FF, Hu YH, Xiong LP, Tu XY, Zhao JH,
Chen SS, Song J and Ye XQ: Enhanced expression of stem cell markers
and drug resistance in sphere-forming non-small cell lung cancer
cells. Int J Clin Exp Pathol. 8:6287–6300. 2015.PubMed/NCBI
|
|
39
|
Liu J, Wang L, Ma L, Xu J, Liu C, Zhang J,
Liu J and Chen R: Significantly increased expression of OCT4 and
ABCG2 in spheroid body-forming cells of the human gastric cancer
MKN-45 cell line. Oncol Lett. 6:891–896. 2013.PubMed/NCBI
|
|
40
|
Abubaker K, Latifi A, Luwor R, Nazaretian
S, Zhu H, Quinn MA, Thompson EW, Findlay JK and Ahmed N: Short-term
single treatment of chemotherapy results in the enrichment of
ovarian cancer stem cell-like cells leading to an increased tumor
burden. Mol Cancer. 12:242013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Vidal SJ, Rodriguez-Bravo V, Galsky M,
Cordon-Cardo C and Domingo-Domenech J: Targeting cancer stem cells
to suppress acquired chemotherapy resistance. Oncogene.
33:4451–4463. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wiechert A, Saygin C, Thiagarajan PS, Rao
VS, Hale JS, Gupta N, Hitomi M, Nagaraj AB, DiFeo A, Lathia JD, et
al: Cisplatin induces stemness in ovarian cancer. Oncotarget.
7:30511–30522. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Bu Y, Jia Q-A, Ren Z-G, Zhang J-B, Jiang
X-M, Liang L, Xue T-C, Zhang Q-B, Wang Y-H, Zhang L, et al:
Maintenance of stemness in oxaliplatin-resistant hepatocellular
carcinoma is associated with increased autocrine of IGF1. PLoS One.
9:e896862014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ress AL, Stiegelbauer V, Schwarzenbacher
D, Deutsch A, Perakis S, Ling H, Ivan C, Calin GA, Rinner B, Gerger
A, et al: Spinophilin expression determines cellular growth, cancer
stemness and 5-flourouracil resistance in colorectal cancer.
Oncotarget. 5:8492–8502. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhang Z, Duan Q, Zhao H, Liu T, Wu H, Shen
Q, Wang C and Yin T: Gemcitabine treatment promotes pancreatic
cancer stemness through the Nox/ROS/NF-κB/STAT3 signaling cascade.
Cancer Lett. 382:53–63. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ayadi M, Bouygues A, Ouaret D, Ferrand N,
Chouaib S, Thiery J-P, Muchardt C, Sabbah M and Larsen AK: Chronic
chemotherapeutic stress promotes evolution of stemness and
WNT/beta-catenin signaling in colorectal cancer cells: Implications
for clinical use of WNT-signaling inhibitors. Oncotarget.
6:18518–18533. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Nör C, Zhang Z, Warner KA, Bernardi L,
Visioli F, Helman JI, Roesler R and Nör JE: Cisplatin induces Bmi-1
and enhances the stem cell fraction in head and neck cancer.
Neoplasia. 16:137–146. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Chowanadisai W, Messerli SM, Miller DH,
Medina JE, Hamilton JW, Messerli MA and Brodsky AS: Cisplatin
resistant spheroids model clinically relevant survival mechanisms
in ovarian tumors. PLoS One. 11:e01510892016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Liu YP, Yang CJ, Huang MS, Yeh CT, Wu AT,
Lee YC, Lai TC, Lee CH, Hsiao YW, Lu J, et al: Cisplatin selects
for multidrug-resistant CD133+ cells in lung
adenocarcinoma by activating Notch signaling. Cancer Res.
73:406–416. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zhang F, Duan S, Tsai Y, Keng PC and Chen
Y, Lee SO and Chen Y: Cisplatin treatment increases stemness
through upregulation of hypoxia-inducible factors by interleukin-6
in non-small cell lung cancer. Cancer Sci. 107:746–754. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yang J, Guo W, Wang L, Yu L, Mei H, Fang
S, Ji P, Liu Y, Liu G and Song Q: Cisplatin-resistant osteosarcoma
cells possess cancer stem cell properties in a mouse model. Oncol
Lett. 12:2599–2605. 2016.PubMed/NCBI
|
|
52
|
Tsai LL, Yu CC, Chang YC, Yu CH and Chou
MY: Markedly increased Oct4 and Nanog expression correlates with
cisplatin resistance in oral squamous cell carcinoma. J Oral Pathol
Med. 40:621–628. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
She JJ, Zhang PG, Wang X, Che XM and Wang
ZM: Side population cells isolated from KATO III human gastric
cancer cell line have cancer stem cell-like characteristics. World
J Gastroenterol. 18:4610–4617. 2012. View Article : Google Scholar : PubMed/NCBI
|
